Bristol Myers Squibb 3Q Growth Portfolio Revenue Rises 12% to $7.66B
Story updates
10:59:11 AM UTC
SquawkNews
Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 58c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY
10:59:13 AM UTC
SquawkNews
Bristol Myers Squibb: In Legacy Portfolio, Revenue Growth Was Primarily Driven by Eliquis in 3Q, Partially Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY